Vertex, in its largest-ever deal, acquires endocrine disease specialist Crinetics for $10B

Vertex Pharmaceuticals has struck a $10 billion deal—its largest ever—to acquire | Vertex Pharmaceuticals has struck a $10 billion deal—its largest ever—to acquire endocrine disease specialist Crinetics Pharmaceuticals. The transaction's two focuses, Palsonify and atumelnant, have combined peak sales potential of more than $5 billion, Vertex said.

Raccontata damarkets.businessinsider.comendpoints.newsbenzinga.cominvestors.comstatnews.combiopharmadive.comfiercepharma.com